Evidence map›Paper›PMID 40004954›Full record

ArticleNutrients2025

The Incretin Effect of Yerba Maté (

Elijah T Cooper-Leavitt, Marley J Shin, Colson G Beus, Alden T Chiu, Genevieve Parker, Jack H Radford, Ethan P Evans, Isaac T Edwards, Juan A Arroyo, Paul R Reynolds and 1 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nutrients, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07240246 (Effect of a Dietary Supplement), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07240246 nacompletednot on this map

Effect of a Dietary Supplement (FitLine TopShape) on the Incretin Response

TypeinterventionalSponsorFFoQSI - Austrian Competence Centre for Feed and Food Quality, Safety & InnovationRan2025 to 2026Enrolled40ConditionsGLP-1, Obesity &Amp, Overweight, Dietary SupplementArmsIntervention: Dietary Supplement with Plant Extracts, Placebo
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Nutrients · 2026
    Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Elijah T Cooper-LeavittDepartment of Cell Biology and Physiology, Brigham Young University, Provo, UT 84602, USA.
Marley J ShinDepartment of Cell Biology and Physiology, Brigham Young University, Provo, UT 84602, USA.
Colson G BeusDepartment of Cell Biology and Physiology, Brigham Young University, Provo, UT 84602, USA.
Alden T ChiuDepartment of Cell Biology and Physiology, Brigham Young University, Provo, UT 84602, USA.
Genevieve ParkerDepartment of Cell Biology and Physiology, Brigham Young University, Provo, UT 84602, USA.
Jack H RadfordDepartment of Cell Biology and Physiology, Brigham Young University, Provo, UT 84602, USA.
Ethan P EvansDepartment of Cell Biology and Physiology, Brigham Young University, Provo, UT 84602, USA.
Isaac T EdwardsDepartment of Cell Biology and Physiology, Brigham Young University, Provo, UT 84602, USA.
Juan A ArroyoDepartment of Cell Biology and Physiology, Brigham Young University, Provo, UT 84602, USA.ORCID 0000-0002-8818-8786
Paul R ReynoldsDepartment of Cell Biology and Physiology, Brigham Young University, Provo, UT 84602, USA.ORCID 0000-0002-0931-3025
Benjamin T BikmanDepartment of Cell Biology and Physiology, Brigham Young University, Provo, UT 84602, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesYerba maté (YM), a traditional herbal beverage made from

resultsYM supplementation significantly increased GLP-1 gene expression and plasma GLP-1 levels compared to controls, with no changes observed in GIP expression or plasma levels. Direct treatment of GLUTag L-cells with YM did not enhance GLP-1 secretion. However, dihydroferulic acid, a microbial metabolite of ferulic acid, markedly stimulated GLP-1 production in L-cells, highlighting a role of gut-mediated metabolism in YM's incretin effects.

conclusionsYM selectively upregulates GLP-1 pathways without affecting GIP, likely through gut-mediated mechanisms. These findings suggest YM as a promising nutraceutical for incretin modulation and metabolic disorder management. Further studies should explore the interplay between YM, the gut microbiota, and incretin pathways to fully realize its therapeutic potential.

Indexed as

Coumaric AcidsIlex paraguariensisIncretinsPlant ExtractsAnimalsFemaleGastric Inhibitory PolypeptideGlucagon-Like Peptide 1Intestinal MucosaJejunumMaleMiceMice, Inbred C57BLCoumaric Acidsferulic acidGastric Inhibitory PolypeptideGlucagon-Like Peptide 1IncretinsPlant Extractsbioactive moleculesdihydroferulic acidferulic acidgastric inhibitor peptideglucagon-like peptide-1gut hormonesincretinincretinsyerba maté

Identifiers

PMID40004954
PMCPMC11858593

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.